BI 905677 / Boehringer Ingelheim - LARVOL DELTA

The potential of ARL4C and its-mediated genes in atherosclerosis and agent development. (PubMed, Front Pharmacol) - "Many agents, including ABCA1 agonists (CS-6253, IMM-H007, RG7273, and R3R-01), FLNA antagonist sumifilam, LRP6 inhibitor BI-905677 and agonist SZN-1326, and SOX2 inhibitor STEMVAC, were investigated in clinical trials. Thus, ARL4C and its regulated genes may be a potential target for drug development. Thus, we focus on the role of ARL4C and its-mediated genes in atherosclerosis and agent development, which provide insights for the identification, research, and drug development of novel targets."

Journal • Review • Atherosclerosis • Cardiovascular • Colorectal Cancer • Hepatology • Liver Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ABCA1 • ALDH1A3 • SNAI2 • SOX2

A phase I dose-escalation study of LRP5/6 antagonist BI 905677 in patients with advanced solid tumors. (PubMed, ESMO Open) - P1 | "The MTD of BI 905677 was set at 2.8 mg/kg every 3 weeks. BI 905677 was well tolerated but a narrow therapeutic range and minimal efficacy led to early termination of the trial."

Journal • Metastases • P1 data • Dyslipidemia • Oncology • Solid Tumor • AXIN2

This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours) (clinicaltrials.gov) - P1 | N=37 | Terminated | Sponsor: Boehringer Ingelheim | Completed ➔ Terminated; Sponsor decision

Metastases • Trial termination • Oncology • Solid Tumor

A phase I, open-label, dose-escalation study investigating a low-density lipoprotein receptor-related protein (LRP) 5/6 inhibitor, BI 905677, in patients with advanced solid tumors (AACR 2022) - P1 | "BI 905677 was well tolerated, with the MTD established as 2.8 mg/kg q3w. An expansion cohort to evaluate the activity of BI 905677 in a molecularly selected population for Wnt ligand dependence is planned."

Clinical • Oncology • Solid Tumor • CTNNB1

This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours) (clinicaltrials.gov) - P1 | N=37 | Completed | Sponsor: Boehringer Ingelheim | Active, not recruiting ➔ Completed

Trial completion • Oncology • Solid Tumor

This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours) (clinicaltrials.gov) - P1 | N=37 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Nov 2022 ➔ Jul 2022

Trial completion date • Oncology • Solid Tumor

This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours) (clinicaltrials.gov) - P1 | N=37 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Jul 2022 ➔ Nov 2022 | Trial primary completion date: Jun 2022 ➔ Sep 2022

Trial completion date • Trial primary completion date • Oncology • Solid Tumor

This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours) (clinicaltrials.gov) - P1 | N=37 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting | N=78 ➔ 37 | Trial completion date: Sep 2023 ➔ May 2022

Enrollment change • Enrollment closed • Trial completion date • Oncology • Solid Tumor

This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours) (clinicaltrials.gov) - P1; N=78; Recruiting; Sponsor: Boehringer Ingelheim; N=60 ➔ 78; Trial completion date: Jun 2022 ➔ Sep 2023; Trial primary completion date: Jun 2022 ➔ Aug 2021

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours) (clinicaltrials.gov) - P1; N=60; Recruiting; Sponsor: Boehringer Ingelheim; Suspended ➔ Recruiting

Clinical • Enrollment open • Oncology • Solid Tumor

[VIRTUAL] Expanding the Druggable Cancer Target Space (AACR 2020) - "BI 1701963 is the first SOS1::KRAS inhibitor to advance to clinical trials and, in combination with RAS/MAPK pathway-targeted drugs, represents an approach to target a broad spectrum of mutant KRAS-driven cancers, including major non-G12C-mutated cancers...BI 905677 is a first-in-class LRP5/6 antagonist in phase 1 studies that effectively targets WNT-driven proliferation and immune escape...BI 905711 is scheduled to enter phase 1 clinical trials in early 2020. Collectively, these three areas of precision medicines promise to significantly expand the druggable target space and offer much-needed therapeutic options to cancer patients."

Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CTNNB1 • KRAS

This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours) (clinicaltrials.gov) - P1; N=60; Suspended; Sponsor: Boehringer Ingelheim; Recruiting ➔ Suspended

Trial suspension